Administration of 2.5 × 107 SPCs from B6 mice to CB6F1 Ifngr1–/– recipient mice led to significantly increased GVHD-induced mortality (Figure 5A) and GVHD target tissue pathology when studied on day 30 after BMT (Supplemental Figure 9). This evidence concerns the gene IFNGR1 and graft versus host disease.